Back to Search Start Over

LRP11 activates β-catenin to induce PD-L1 expression in prostate cancer.

Authors :
Gan, Sishun
Ye, Jianqing
Li, Jian
Hu, Chuanyi
Wang, Junkai
Xu, Da
Pan, Xiuwu
Chu, Chuanmin
Chu, Jian
Zhang, Jing
Zheng, Jingcun
Zhang, Xiangmin
Xu, Jidong
Zhang, He
Qu, Fajun
Cui, Xingang
Source :
Journal of Drug Targeting; Jun2020, Vol. 28 Issue 5, p508-515, 8p
Publication Year :
2020

Abstract

Prostate cancer (PRAD) is associated with abnormal cholesterol metabolism and low-density lipoprotein (LDL) receptor-related protein (LRP) family is essential for the homeostasis of cholesterol. Immune check points like PD-L1 are vital for tumour cells to evade immune attack. However, the potential cross-talk between these two pathways has not been explored before in PRAD. Insight from the regulation mechanism of PD-L1 in PRAD may help to optimise PD-L1 based immunotherapy. In this study, we investigated a regulation network of LRP11/β-catenin/PD-L1 in PRAD. We showed that the expression of LRP11 and PD-L1 was up-regulated in PRAD compared to paired normal tissues. LRP11 expression was positively correlated to PD-L1 expression in PRAD tissues. Further experiments in two PRAD cell lines with LRP11 over-expression and knockdown showed that LRP11 induced PD-L1 expression through β-catenin signalling. In addition, LRP11 over-expression in PRAD cell line induced immunosuppression of Jurkat cell in in-vitro co-culture system. The effects of LRP11 could be blocked by neutralising LRP11 or PD-L1 antibody. Our results provide evidence for a novel regulation mechanism of PD-L1 expression in PRAD and LRP11 may be a potential therapeutic target in PRAD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1061186X
Volume :
28
Issue :
5
Database :
Complementary Index
Journal :
Journal of Drug Targeting
Publication Type :
Academic Journal
Accession number :
146850103
Full Text :
https://doi.org/10.1080/1061186X.2019.1687710